Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12448-12458

  de Giorgi, Ugo ^a   Caroli, Paola ^a   Burgio, Salvatore L ^a   Menna, Cecilia ^a   Conteduca, Vincenza ^a   Bianchi, Emanuela ^a   Fabbri, Francesca ^a   Carretta, Elisa ^a   Amadori, Dino ^a   Paganelli, Giovanni ^a   Matteucci, Federica ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

18F fluorocholine positron emission tomography; Abiraterone; Bone flare; Castration resistant prostate cancer; PSA

Indexed keywords

ABIRATERONE; DOCETAXEL; FLUOROCHOLINE F 18; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CHOLINE; FLUOROCHOLINE; RADIOISOTOPE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; CANCER PROGNOSIS; CANCER REGRESSION; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; DRUG SAFETY; FLUID RETENTION; FOLLOW UP; GLEASON SCORE; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMAGING SOFTWARE; KIDNEY FAILURE; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; OVERALL SURVIVAL; PET SCANNER; PREDICTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTATECTOMY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR FLARE; UNIVARIATE ANALYSIS; VERY ELDERLY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MORTALITY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SCINTISCANNING;

AGED; ANDROSTENES; ANTINEOPLASTIC AGENTS; CHOLINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84920031396     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2558     Document Type: Article

References (33)

1. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009; 27:3742-3748.
2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368:138-148.
3. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, et al. Abiraterone acetate for treatment of metastatic castrationresistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13:983-992.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364:1995-2005.
5. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148-1159.
6. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001; 42:1805-1814.
7. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008; 35:1766-1774.
8. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013; 64:106-117.
9. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002; 168:273-280.
10. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012; 15:45-55.
11. Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K, Pascal O, Cussenot O, Talbot JN. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging. 2011; 55:448-457.
12. Kwee SA, Coel MN, Ly BH, Lim J. (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. Ann Nucl Med. 2009; 23:541-548.
13. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009; 27:3303-3311.
14. De Giorgi U, Mego M, Rohren EM, Liu P, Hndy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010; 51:1213-1218.
15. Ryan CJ, Londhe A, Molina A, Smith MR, De Bono JS, Mulders P, Rathkopf DE, Saad F, Logothetis C, Fizazi K, Scher HI, Small EJ, Matheny S, et al. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302 [abstr 5010]. J Clin Oncol. 2013; :31.
16. Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, Fabbri P, Montanari M, Carretta E, Menna C, De Giorgi U. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014 Jun 12; [Epub ahead of print].
17. Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, Cappia S, Ari MM, Tampellini M, Fontana D, Gubetta L, Angeli A, Dogliotti L. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol. 2001; 12:S159-164.
18. Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, De Giorgi U. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer. 2014; 21:487-493.
19. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354:496-507.
20. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004; 45:17-21.
21. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol. 2006; 79:32-36.
22. Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. Oncotarget. 2014; 5:4050-4059.
23. Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, John H, Binkert CA, Boesiger P, Gutzeit A. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology. 2010; 257:523-531.
24. Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, de Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging. 2014; 39:1049-1078.
25. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011; 17:4854-4861.
26. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with 18F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010; 37:2188-2193.
27. Conteduca V, Aieta M, Costantini M, Amadori D, De Giorgi U. Current and emerging strategies on neuroendocrine prostate cancer. Crit Rev Oncol Hematol. 2014; 92:11-24.
28. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, et al. Tumor localization of 16beta-18F-fluoro-5alphadihydrotestosterone versus 18F-FDG in patients with progressive metastatic prostate cancer. J Nucl Med. 2004; 45:366-373.
29. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioicacid[18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17:7645-7653.
30. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostatespecific membrane antigen. Proc Natl Acad Sci U S A. 2011; 108:9578-9782.
31. Mawlawi O, Podoloff DA, Kohlmyer S, Williams JJ, Stearns CW, Culp RF, Macapinlac H. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med. 2004; 45:1734-1742.
32. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations-European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35:1773-1782.
33. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008; 247: 189-196.